Apomorphine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Apomorphine
| |
| Systematic (IUPAC) name | |
| 5,6,6a,7-Tetrahydro-6-methyl-4H- dibenzo[de,g]quinolin-10,11-diol (?) | |
| Identifiers | |
| CAS number | |
| ATC code | G04 N04BC07 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H17NO2 |
| Mol. mass | 267.322 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 100% following sc injection |
| Protein binding | ~50% |
| Metabolism | hepatic |
| Half life | 40 minutes (range 30-60 minutes) |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
II (California), non-scheduled (Rest of USA) |
| Routes | sc |
|
WikiDoc Resources for Apomorphine | |
|
Articles | |
|---|---|
|
Most recent articles on Apomorphine Most cited articles on Apomorphine | |
|
Media | |
|
Powerpoint slides on Apomorphine | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Apomorphine at Clinical Trials.gov Clinical Trials on Apomorphine at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Apomorphine
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Apomorphine Discussion groups on Apomorphine Patient Handouts on Apomorphine Directions to Hospitals Treating Apomorphine Risk calculators and risk factors for Apomorphine
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Apomorphine | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Business | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-632-7753
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Apomorphine is a type of dopaminergic agonist, a morphine derivative (but does not actually contain morphine, or bind to opioid receptors). Apomorphine is a relatively non-selective dopamine receptor agonist, having possible slightly higher affinity for D2-like dopamine receptors.
Historically, apomorphine has been tried for a variety of uses including psychiatric treatment of homosexuality in the early 20th century. Currently, apomorphine is used in the treatment of Parkinson's disease and (under the name Uprima) erectile dysfunction. It was also successfully used in the treatment of heroin addiction, a purpose for which it was championed by the author William S. Burroughs. It is a potent emetic, meaning that it should not be administered without an antiemetic such as domperidone. The emetic properties of apomorphine are exploited in veterinary medicine to induce therapeutic emesis in canines that have recently ingested toxic or foreign substances.
For treatment of erectile dysfunction, it is believed that dopamine receptors in the hypothalamic region of the brain are the main target, as although dopamine receptors in the penis do facilitate erection, they do so far more weakly than those in the brain.[1]
Apomorphine is clear as a liquid but stains green. Therefore care must be taken to avoid splashes. Apormophine does not remain stable for more than 24 hours in a plastic container, so syringes are discarded if not used within 24 hours.
Use in Parkinson's disease
First mooted as a treatment for Parkinson's disease as early as 1951,[2] its clinical use was first reported in 1970 by Cotzias et al,[3] although its emetic properties and short half-life made oral use impractical. A later study found that combining the drug with the antiemetic domperidone improved results significantly.[4]
Therapeutic use in Parkinson's disease is effective because of the drugs strong dopaminergic action, with a rapid effect (within 3-20 minutes of injection) but a brief duration.[5] Whilst apomorphine can be used in combination with l-dopa, the intention is usually to wean patients off of this, as by this stage they will probably be experiencing a great deal of dopa-induced dyskinesias and "off" periods.[5] Following a successful apomorphine challenge, training of patient and caregiver, and careful dose titration, there is no reason why an apomorphine pump can not be an effective monotherapy.[5]
Erectile dysfunction
Apomorphine hydrochloride (trade name "Uprima") is used in the treatment of erectile dysfunction (male impotence). Its mode of stimulating dopamine in the brain which is believed to enhance the sexual response. It was found to be of poor efficacy[6] in a large scale study by Researchers at the UK's Drug Safety Research Unit and University of Portsmouth and discontinued in the UK in January 2006.[6] Around 65-70% of doctors felt it was ineffective, with 60% of over 11,000 patients (avg age 61) discontinuing in month 1 and a further 23% in month 2.[6] [7] Nonetheless some sources continue to supply the drug claiming it is effective.[8]
References
- ↑ Matsumoto K, Yoshida M, Andersson K, Hedlund P (2005). "Effects in vitro and in vivo by apomorphine in the rat corpus cavernosum.". Br J Pharmacol 146 (2): 259-67. PMID 16025145.
- ↑ Schwab R, Amador L, Lettvin J. "Apomorphine in Parkinson's disease.". Trans Am Neurol Assoc 56: 251-3. PMID 14913646.
- ↑ Cotzias G, Papavasiliou P, Fehling C, Kaufman B, Mena I (1970). "Similarities between neurologic effects of L-dopa and of apomorphine.". N Engl J Med 282 (1): 31-3. PMID 4901383.
- ↑ Corsini G, Del Zompo M, Gessa G, Mangoni A (1979). "Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.". Lancet 1 (8123): 954-6. PMID 87620.
- ↑ 5.0 5.1 5.2 Chaudhuri K, Clough C (1998). "Subcutaneous apomorphine in Parkinson's disease.". BMJ 316 (7132): 641. PMID 9522772.
- ↑ 6.0 6.1 6.2 Pharmaceutical Business Review, "Study shows Abbott's Uprima ineffective for most UK patients"
- ↑ MedicineNet study review
- ↑ For example: http://www.healthexpress.co.uk/Uprima.cfm
External links
- PDSP Ki database
- Apomorphine - Frequently Asked Questions. Britannia Pharmaceuticals.
- Andrew Lees and Kirsten Turner (2002). "Apomorphine for Parkinson’s Disease" (PDF). Practical Neurology 2: 280-287. doi:10.1046/j.1474-7766.2002.00086.x. - Detailed usage guide for Apomorphine pumps for Parkinson's
Anti-parkinson drugs: dopaminergic agents (N04B) | |
|---|---|
| Dopa and derivatives | Levodopa, Melevodopa, Etilevodopa |
| Adamantane derivatives | Amantadine |
| Dopamine agonists | Apomorphine, Bromocriptine, Cabergoline, Dihydrexidine, Dihydroergocryptine mesylate, Fenoldopam, Lisuride, Pergolide, Piribedil, Pramipexole, Quinpirole, Ropinirole, Rotigotine, SKF 38393, SKF 82958 |
| MAOIs | Selegiline, Rasagiline |
| Other | Tolcapone, Entacapone, Budipine |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
